Abivax SA, a clinical-stage biotechnology company specializing in innovative therapies for chronic inflammatory diseases, has announced a significant upcoming Key Opinion Leader (KOL) webcast featuring renowned gastroenterology expert Dr. David T. Rubin. The virtual event, scheduled for March 17, 2025, at 9:00 a.m. EDT, will focus on the company's pivotal ABTECT Phase 3 trial investigating obefazimod for ulcerative colitis treatment.
Expert Insights on Ulcerative Colitis Treatment
Dr. Rubin, who serves as Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago, will share his expertise on the evolving treatment landscape for ulcerative colitis. His presentation will specifically address the potential impact of obefazimod in treating adults with moderately to severely active ulcerative colitis.
ABTECT Trial and Unmet Medical Needs
The webcast will provide a detailed examination of Abivax's ABTECT Phase 3 trial, highlighting the drug candidate's development progress and its potential role in addressing critical gaps in current ulcerative colitis treatment options. Obefazimod (ABX464) represents a novel approach to treating chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms to stabilize immune response.
Interactive Discussion Format
Following the main presentation, the event will feature an interactive Q&A session, allowing participants to engage directly with both Dr. Rubin and Abivax's management team. This format will provide stakeholders with the opportunity to gain deeper insights into the trial's objectives and potential clinical implications.
The webcast reflects Abivax's commitment to advancing innovative therapeutic solutions in the field of chronic inflammatory diseases, with operations based in both France and the United States. Healthcare professionals, investors, and interested parties can register for the event through the company's dedicated registration portal.
